Filing Flows

Filing Flows › Companies › Impact Biomedical › Cash flow

Impact Biomedical cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$470K in Q2 2026 · −$508K over twelve months

Operating cash flow$470K
Free cash flow+$470K

Analysis

In Q2 2026, Impact Biomedical generated $470K of operating cash flow. That is $1.2M more than in Q2 2025 (−$694K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$508K; the largest uses were operating cash flow ($508K); besides operations, cash came from other investing ($3K); the cash balance fell by $614K.

Operating cash flow was $470K against net income of −$700K. The largest differences: depreciation & amortization +$284K, payables +$93K, prepaid and other assets +$44K.

Free cash flow

Impact Biomedical: free cash flow by quarterImpact Biomedical: free cash flow by quarter−$1.0MQ3 2024−$986KQ4 2024−$682KQ1 2025−$694KQ2 2025−$613KQ3 2025$99KQ4 2025−$464KQ1 2026$470KQ2 2026
Operating cash flow less capital spending.
Impact Biomedical: operating cash flow against capital spendingImpact Biomedical: operating cash flow against capital spendingOperating cash flowCapital spending−$1.0M$0Q3 2024−$986K$0Q4 2024−$682K$0Q1 2025−$694K$0Q2 2025−$613K$0Q3 2025$99K$0Q4 2025−$464K$0Q1 2026$470K$0Q2 2026
Latest (Q2 2026): Operating cash flow $470K, Capital spending $0.

Capital allocation, year by year

Impact Biomedical: where the cash came from (up) and went (down), by fiscal yearImpact Biomedical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2022: Operating cash flow −$2.2MFY2022FY2023: Operating cash flow −$2.9MFY2023: Net borrowing $2.9M$2.9MFY2023FY2024: Operating cash flow −$2.9MFY2024: Net borrowing $1.1MFY2024: Shares issued $3.7M$4.8MFY2024FY2025: Operating cash flow −$1.9MFY2025
Over these 4 years operating cash flow totalled −$9.8M; the largest uses were operating cash flow ($9.8M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$10K
Debtnone
Net cash$10K
Cash runway0 months

Impact Biomedical is burning cash: its operations consume cash, a free cash flow of −$508K a year at the current rate against $10K of cash and investments: a runway of about 0 months before any new financing.

Where the cash came from and went

Impact Biomedical: sources (+) and uses (−) of cash, Q2 2026Impact Biomedical: sources (+) and uses (−) of cash, Q2 2026Not reconciled−$482KOperating cash flow$470KCash drawn (+) / kept (−)$10KOther investing$2K
Impact Biomedical: sources (+) and uses (−) of cash, TTM to Q2 2026Impact Biomedical: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$614KOperating cash flow−$508KNot reconciled−$109KOther investing$3K

From profit to cash

Impact Biomedical: net income to operating cash flow, Q2 2026Impact Biomedical: net income to operating cash flow, Q2 2026Net income−$700KDepreciation & amortization$284KPayables$93KAccrued liabilities$38KPrepaid and other assets$44KOperating cash flow$470K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q4 20251316010191
Q3 202510204466651980-6294
Q2 202526004436253190-6227

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026$470K—$10K$470K
Q1 2026−$464K−$1K−$17K−$464K
Q4 2025$99K—$9K$99K
Q3 2025−$613K—$612K−$613K
Q2 2025−$694K—$694K−$694K
Q1 2025−$682K—$681K−$682K
Q4 2024−$986K$317K$669K−$986K
Q3 2024−$1.0M−$60K−$2.7M−$1.0M

Impact Biomedical: income statement and cash flow

Impact Biomedical, Q2 2026: revenue $3K (-57% year over year). The chart follows the revenue to costs, profit and cash.

Impact Biomedical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.